Chemical inhibition of VEGF signaling reduced tumor growth in vivo with an associated decrease in angiogenesis, implicating VEGF inhibitors as promising therapeutic agents for ERMS. The gene discussed is VEGFA; the disease is embryonal rhabdomyosarcoma.